Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Amino acids serve as substrates for protein synthesis and intermediary metabolism; dextrose provides caloric replacement; electrolytes maintain acid-base and electrolyte balance.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day administered as a continuous or intermittent infusion, providing 4.25% amino acids and 5% dextrose. Rate adjusted based on metabolic needs and tolerance.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Not applicable as a composite; amino acids have varying half-lives (minutes). Dextrose: glucose half-life ~1.5-2.5 hours in healthy individuals. Clinical context: continuous infusion maintains steady state.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Amino acids: renal elimination of unmodified amino acids is minimal (<5%); most nitrogen is excreted as urea via kidneys. Dextrose: fully metabolized, negligible renal excretion of intact glucose. Electrolytes: renally excreted.
Category C
Category C
Amino Acid Solution
Amino Acid Solution